António Almeida

António Almeida is a Full Professor and Founding Dean at Católica Medical School, Católica University, Lisbon, Portugal, and Head of Department at Hospital da Luz. He is also affiliated with the Center for Interdisciplinary Research in Health (CIIS). His academic and clinical leadership spans hematology, medical education, and translational research.

Education

• Medical Degree, Cambridge University, UK (1993)
• PhD, Imperial College, London (2007)
• Specialist Training in Haematology, UK (2002)

Dr. Almeida’s research centers on myeloproliferative and myelodysplastic syndromes, with a focus on epigenetic regulation of transcription. He leads a hematology epigenetics research group and is the national principal investigator for multiple clinical trials in CML and MDS. His scholarly output includes over 60 publications in high-impact journals such as New England Journal of Medicine, Nature Medicine, and Blood. Analysis of his recent articles reveals a strong trend in clinical guidelines, genomic profiling, and personalized treatment strategies in hematologic malignancies, particularly AML and MDS.

Scientific and Professional Leadership

• Chair, European Hematology Association (EHA) Curriculum Committee
• Member, EHA Education Committee
• EHA Secretary, Executive Board
• Author of book chapters and over 60 peer-reviewed articles

Dr. Almeida is deeply involved in medical education at both undergraduate and postgraduate levels. He has contributed to curriculum development and served as an examiner in academic evaluations. His work also aligns with UN Sustainable Development Goal 3 (Good Health and Well-being) and Goal 4 (Quality Education). He leads and participates in multiple research projects, including those on dementia prevention and AML biomarker discovery, demonstrating a broad interdisciplinary impact.

Research Groups and Projects

• Haematology Epigenetic Research Group (Leader)
• CIIS – Center for Interdisciplinary Research in Health
• SPIT-it-AML: Saliva-based prognostic markers in AML
• DemenPrev: Dementia prevention through randomized trials